Apogee Therapeutics (APGE)
Apogee Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
4.2M
Short interest
settlement 2026-08-31
3.5
Days to cover
+0.2 days vs prior
41.7%
Short share of volume
2026-09-02
1
Fails to deliver
settlement 2026-09-03
Mon 9 Nov
Next earnings
estimated date
-$738K
Insider flow, 90 days
0 buys, 1 sells
As of 2026-09-08.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 31 August 2026, short interest in APGE is 4,203,052 shares, down 14,157 shares over the last month. Over the last 48 readings it ranged from 4,133,296 shares (15 July 2026) to 10,526,394 shares (29 May 2026). The latest reading sits at the bottom of that range. At the reported average volume of 1.2M shares a day that is 3.5 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/apge" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-08-31 | 4,203,052 | -1.6% | 1,212,887 | 3.47 |
| 2026-08-14 | 4,273,438 | +1.3% | 1,324,883 | 3.23 |
| 2026-07-31 | 4,217,209 | +2.0% | 1,047,072 | 4.03 |
| 2026-07-15 | 4,133,296 | -19.9% | 1,740,933 | 2.37 |
| 2026-06-30 | 5,161,455 | -50.7% | 10,062,043 | 1.00 |
| 2026-06-15 | 10,477,522 | -0.5% | 1,016,327 | 10.31 |
| 2026-05-29 | 10,526,394 | +12.3% | 1,124,634 | 9.36 |
| 2026-05-15 | 9,371,143 | -1.3% | 591,084 | 15.85 |
| 2026-04-30 | 9,489,537 | -0.8% | 663,969 | 14.29 |
| 2026-04-15 | 9,567,729 | -1.7% | 616,265 | 15.53 |
| 2026-03-31 | 9,729,380 | +10.6% | 1,603,880 | 6.07 |
| 2026-03-13 | 8,798,347 | +2.1% | 882,938 | 9.96 |
| 2026-02-27 | 8,619,325 | -0.9% | 610,700 | 14.11 |
| 2026-02-13 | 8,700,530 | -2.4% | 959,948 | 9.06 |
| 2026-01-30 | 8,913,346 | +10.1% | 1,203,004 | 7.41 |
| 2026-01-15 | 8,093,742 | -6.6% | 1,038,933 | 7.79 |
| 2025-12-31 | 8,664,816 | +2.3% | 960,179 | 9.02 |
| 2025-12-15 | 8,472,837 | +7.3% | 958,132 | 8.84 |
| 2025-11-28 | 7,898,663 | -0.4% | 608,396 | 12.98 |
| 2025-11-14 | 7,931,680 | -0.3% | 798,505 | 9.93 |
| 2025-10-31 | 7,954,445 | -6.9% | 708,706 | 11.22 |
| 2025-10-15 | 8,545,761 | -9.6% | 1,074,878 | 7.95 |
| 2025-09-30 | 9,448,327 | +5.6% | 550,373 | 17.17 |
| 2025-09-15 | 8,947,262 | -2.8% | 568,077 | 15.75 |
| 2025-08-29 | 9,201,255 | +0.8% | 400,535 | 22.97 |
| 2025-08-15 | 9,123,436 | +8.7% | 565,765 | 16.13 |
| 2025-07-31 | 8,396,660 | -8.7% | 678,763 | 12.37 |
| 2025-07-15 | 9,192,676 | +6.1% | 1,794,158 | 5.12 |
| 2025-06-30 | 8,663,116 | -5.6% | 811,709 | 10.67 |
| 2025-06-13 | 9,175,746 | -9.6% | 976,357 | 9.40 |
| 2025-05-30 | 10,152,654 | -0.6% | 514,227 | 19.74 |
| 2025-05-15 | 10,209,991 | -1.6% | 628,665 | 16.24 |
| 2025-04-30 | 10,381,113 | +7.8% | 512,383 | 20.26 |
| 2025-04-15 | 9,629,722 | +11.5% | 895,609 | 10.75 |
| 2025-03-31 | 8,633,474 | +5.8% | 683,994 | 12.62 |
| 2025-03-14 | 8,161,011 | +5.1% | 892,548 | 9.14 |
| 2025-02-28 | 7,762,784 | -6.7% | 637,486 | 12.18 |
| 2025-02-14 | 8,321,096 | -5.8% | 489,990 | 16.98 |
| 2025-01-31 | 8,831,060 | +3.9% | 504,915 | 17.49 |
| 2025-01-15 | 8,502,020 | +5.1% | 533,304 | 15.94 |
| 2024-12-31 | 8,087,434 | +1.4% | 376,184 | 21.50 |
| 2024-12-13 | 7,973,039 | +8.3% | 740,254 | 10.77 |
| 2024-11-29 | 7,360,872 | +11.1% | 456,433 | 16.13 |
| 2024-11-15 | 6,623,233 | -2.7% | 464,839 | 14.25 |
| 2024-10-31 | 6,809,612 | -0.8% | 259,452 | 26.25 |
| 2024-10-15 | 6,865,071 | -5.0% | 398,810 | 17.21 |
| 2024-09-30 | 7,225,793 | -11.7% | 521,536 | 13.85 |
| 2024-09-13 | 8,185,156 | -1.1% | 443,498 | 18.46 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 September 2026, the short share of APGE volume is 41.7%, up 26.7 points over the last five sessions. Over the last 30 readings it ranged from 8.2% (5 August 2026) to 61.4% (24 August 2026). The latest reading is 12.6 points above the 30-session average of 29.1%, on 341K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-09-02 | 142K | 341K | 41.7% | 1,800 |
| 2026-09-01 | 58K | 579K | 10.0% | 1 |
| 2026-08-31 | 69K | 216K | 31.9% | 88 |
| 2026-08-28 | 53K | 115K | 46.5% | 0 |
| 2026-08-27 | 44K | 250K | 17.5% | 0 |
| 2026-08-26 | 106K | 708K | 15.0% | 0 |
| 2026-08-25 | 49K | 156K | 31.6% | 1 |
| 2026-08-24 | 244K | 398K | 61.4% | 0 |
| 2026-08-21 | 91K | 402K | 22.7% | 9,378 |
| 2026-08-20 | 102K | 603K | 16.9% | 155 |
| 2026-08-19 | 58K | 607K | 9.5% | 0 |
| 2026-08-18 | 82K | 373K | 22.1% | 0 |
| 2026-08-17 | 105K | 390K | 26.9% | 8,140 |
| 2026-08-14 | 406K | 772K | 52.6% | 1,524 |
| 2026-08-13 | 95K | 323K | 29.5% | 2,011 |
| 2026-08-12 | 63K | 282K | 22.3% | 2 |
| 2026-08-11 | 205K | 558K | 36.8% | 1 |
| 2026-08-10 | 57K | 212K | 26.7% | 17 |
| 2026-08-07 | 95K | 676K | 14.0% | 1,019 |
| 2026-08-06 | 76K | 408K | 18.5% | 2 |
| 2026-08-05 | 82K | 1.0M | 8.2% | 6,914 |
| 2026-08-04 | 466K | 1.5M | 30.2% | 2,000 |
| 2026-08-03 | 93K | 300K | 31.0% | 0 |
| 2026-07-31 | 108K | 812K | 13.3% | 18 |
| 2026-07-30 | 64K | 258K | 24.7% | 0 |
| 2026-07-29 | 96K | 324K | 29.4% | 385 |
| 2026-07-28 | 85K | 305K | 28.0% | 429 |
| 2026-07-27 | 79K | 160K | 49.3% | 5,010 |
| 2026-07-24 | 49K | 82K | 60.3% | 0 |
| 2026-07-23 | 77K | 174K | 44.1% | 1,117 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 3 September 2026, the fails-to-deliver balance in APGE is 1 share, down 1 share over the last settlement date. Over the last 30 readings it ranged from 1 share (5 August 2026) to 333,212 shares (29 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-03 | 1 | $135.07 | $135 |
| 2026-08-31 | 2 | $134.97 | $270 |
| 2026-08-27 | 35 | $134.95 | $5K |
| 2026-08-25 | 45 | $134.79 | $6K |
| 2026-08-11 | 26 | $134.65 | $4K |
| 2026-08-10 | 8 | $134.84 | $1K |
| 2026-08-07 | 28 | $134.49 | $4K |
| 2026-08-05 | 1 | $134.19 | $134 |
| 2026-08-04 | 3 | $134.11 | $402 |
| 2026-07-30 | 3,718 | $134.20 | $499K |
| 2026-07-29 | 17 | $134.17 | $2K |
| 2026-07-20 | 8,230 | $134.00 | $1.1M |
| 2026-07-17 | 32 | $134.08 | $4K |
| 2026-07-06 | 581 | $132.91 | $77K |
| 2026-07-02 | 1,245 | $132.77 | $165K |
| 2026-07-01 | 8 | $132.73 | $1K |
| 2026-06-30 | 1,496 | $132.61 | $198K |
| 2026-06-29 | 333,212 | $132.55 | $44.2M |
| 2026-06-24 | 32,232 | $132.88 | $4.3M |
| 2026-06-22 | 52,475 | $90.38 | $4.7M |
| 2026-06-18 | 49,990 | $88.43 | $4.4M |
| 2026-06-16 | 96 | $86.19 | $8K |
| 2026-06-08 | 26,344 | $86.92 | $2.3M |
| 2026-06-05 | 100 | $90.90 | $9K |
| 2026-06-03 | 375 | $78.71 | $30K |
| 2026-05-29 | 206 | $77.82 | $16K |
| 2026-05-28 | 660 | $77.75 | $51K |
| 2026-05-26 | 8 | $81.16 | $649 |
| 2026-05-22 | 45 | $82.43 | $4K |
| 2026-05-19 | 105 | $78.75 | $8K |
Insider trades
SEC Form 4, newest first. JSONInsiders at APGE reported 1 open-market sell worth $738K in the last 90 days and no open-market buys. Latest filing: Fairmount Funds Management LLC (Director) on 2026-09-03.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-03 | Fairmount Funds Management LLC | Director | Returned to company | 51K | price not stated in the filing | not stated | 0 |
| 2026-09-03 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Returned to company | 921K | price not stated in the filing | not stated | 0 |
| 2026-09-03 | Henderson Jane | Chief Financial Officer | Returned to company | 158K | price not stated in the filing | not stated | 0 |
| 2026-09-03 | Fox Jennifer A. | Director | Returned to company | 35K | price not stated in the filing | not stated | 0 |
| 2026-09-03 | Dambkowski Carl | Chief Medical Officer | Returned to company | 167K | price not stated in the filing | not stated | 0 |
| 2026-09-03 | JONES WILLIAM A JR | Director | Returned to company | 35K | price not stated in the filing | not stated | 0 |
| 2026-09-03 | McKenna Mark C. | Director | Returned to company | 20K | price not stated in the filing | not stated | 0 |
| 2026-09-03 | Fairmount Funds Management LLC | Director | Returned to company | 51K | price not stated in the filing | not stated | 0 |
| 2026-09-03 | Fairmount Funds Management LLC | Director | Returned to company | 341K | price not stated in the filing | not stated | 0 |
| 2026-09-03 | Shah Nimish P | Director | Returned to company | 1.8M | $135.11 | $236.4M | 0 |
| 2026-09-02 | Dambkowski Carl | Chief Medical Officer | Returned to company | 1K | $135.06 | $186K | 167K |
| 2026-08-07 | Fairmount Funds Management LLC | Director | Exercise or conversion | 10K | $43.85 | $455K | 341K |
| 2026-08-07 | Fairmount Funds Management LLC | Director | Exercise or conversion | 32K | $17.00 | $541K | 330K |
| 2026-08-05 | Dambkowski Carl | Chief Medical Officer | Sell | 6K | $134.17 | $738K | 168K |
| 2026-08-05 | Dambkowski Carl | Chief Medical Officer | Exercise or conversion | 4K | $22.86 | $94K | 174K |
| 2026-07-24 | Henderson Jane | Chief Financial Officer | Gift | 15K | $0.00 | $0 | 158K |
| 2026-07-14 | Dambkowski Carl | Chief Medical Officer | Gift | 8K | $0.00 | $0 | 170K |
| 2026-07-10 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Gift | 75K | $0.00 | $0 | 921K |
| 2026-07-08 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 20K | $133.63 | $2.7M | 996K |
| 2026-07-01 | Dambkowski Carl | Chief Medical Officer | Sell | 6K | $132.74 | $730K | 178K |
| 2026-07-01 | Dambkowski Carl | Chief Medical Officer | Exercise or conversion | 4K | $22.86 | $94K | 183K |
| 2026-06-22 | Dambkowski Carl | Chief Medical Officer | Sell | 26K | $132.60 | $3.5M | 179K |
| 2026-06-22 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 80K | $132.54 | $10.6M | 1.0M |
| 2026-06-10 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 614 | $86.89 | $53K | 1.1M |
| 2026-06-10 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 2K | $86.27 | $199K | 1.1M |
| 2026-06-10 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 2K | $85.19 | $134K | 1.1M |
| 2026-06-10 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 1K | $84.18 | $91K | 1.1M |
| 2026-06-10 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 8K | $82.78 | $634K | 1.1M |
| 2026-06-10 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 7K | $82.21 | $557K | 1.1M |
| 2026-06-03 | Dambkowski Carl | Chief Medical Officer | Sell | 6K | $78.71 | $433K | 206K |
| 2026-06-03 | Dambkowski Carl | Chief Medical Officer | Exercise or conversion | 4K | $22.86 | $94K | 211K |
| 2026-05-13 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 1K | $82.58 | $111K | 1.1M |
| 2026-05-13 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 19K | $82.05 | $1.5M | 1.1M |
| 2026-05-06 | Dambkowski Carl | Chief Medical Officer | Sell | 2K | $84.60 | $152K | 207K |
| 2026-05-06 | Dambkowski Carl | Chief Medical Officer | Sell | 4K | $83.92 | $311K | 209K |
| 2026-05-06 | Dambkowski Carl | Chief Medical Officer | Exercise or conversion | 4K | $22.86 | $94K | 213K |
| 2026-05-01 | Henderson Jane | Chief Financial Officer | Sell | 289 | $83.16 | $24K | 173K |
| 2026-05-01 | Henderson Jane | Chief Financial Officer | Sell | 900 | $82.60 | $74K | 174K |
| 2026-05-01 | Henderson Jane | Chief Financial Officer | Sell | 811 | $81.02 | $66K | 175K |
| 2026-04-16 | Henderson Jane | Chief Financial Officer | Sell | 2K | $90.00 | $180K | 175K |
| 2026-04-16 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Exercise or conversion | 3K | $22.86 | $69K | 1.1M |
| 2026-04-08 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 200 | $85.00 | $17K | 1.1M |
| 2026-04-08 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 2K | $83.26 | $167K | 1.1M |
| 2026-04-08 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 18K | $82.48 | $1.5M | 1.1M |
| 2026-04-01 | Dambkowski Carl | Chief Medical Officer | Sell | 100 | $85.89 | $9K | 208K |
| 2026-04-01 | Dambkowski Carl | Chief Medical Officer | Sell | 3K | $85.33 | $231K | 208K |
| 2026-04-01 | Dambkowski Carl | Chief Medical Officer | Sell | 3K | $84.31 | $227K | 211K |
| 2026-04-01 | Dambkowski Carl | Chief Medical Officer | Exercise or conversion | 4K | $22.86 | $94K | 214K |
| 2026-04-01 | Henderson Jane | Chief Financial Officer | Sell | 1K | $85.46 | $94K | 177K |
| 2026-04-01 | Henderson Jane | Chief Financial Officer | Sell | 900 | $84.46 | $76K | 178K |
| 2026-03-25 | Henderson Jane | Chief Financial Officer | Sell | 2K | $85.00 | $170K | 179K |
| 2026-03-11 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 3K | $75.86 | $259K | 1.2M |
| 2026-03-11 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 8K | $74.83 | $615K | 1.2M |
| 2026-03-11 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 8K | $74.29 | $621K | 1.2M |
| 2026-03-04 | Dambkowski Carl | Chief Medical Officer | Sell | 200 | $73.26 | $15K | 210K |
| 2026-03-04 | Dambkowski Carl | Chief Medical Officer | Sell | 2K | $71.98 | $149K | 210K |
| 2026-03-04 | Dambkowski Carl | Chief Medical Officer | Sell | 3K | $70.33 | $227K | 212K |
| 2026-03-04 | Dambkowski Carl | Chief Medical Officer | Exercise or conversion | 4K | $22.86 | $94K | 215K |
| 2026-03-02 | Henderson Jane | Chief Financial Officer | Sell | 300 | $69.43 | $21K | 183K |
| 2026-03-02 | Henderson Jane | Chief Financial Officer | Sell | 406 | $71.66 | $29K | 181K |
| 2026-03-02 | Henderson Jane | Chief Financial Officer | Sell | 994 | $70.45 | $70K | 182K |
| 2026-03-02 | Henderson Jane | Chief Financial Officer | Sell | 300 | $68.27 | $20K | 183K |
| 2026-02-11 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 955 | $64.99 | $62K | 1.2M |
| 2026-02-11 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 8K | $63.73 | $481K | 1.2M |
| 2026-02-11 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 11K | $62.96 | $724K | 1.2M |
| 2026-02-04 | Dambkowski Carl | Chief Medical Officer | Sell | 200 | $68.94 | $14K | 211K |
| 2026-02-04 | Dambkowski Carl | Chief Medical Officer | Sell | 100 | $67.88 | $7K | 211K |
| 2026-02-04 | Dambkowski Carl | Chief Medical Officer | Sell | 1K | $66.85 | $87K | 211K |
| 2026-02-04 | Dambkowski Carl | Chief Medical Officer | Sell | 1K | $65.83 | $93K | 213K |
| 2026-02-04 | Dambkowski Carl | Chief Medical Officer | Sell | 2K | $64.88 | $161K | 214K |
| 2026-02-04 | Dambkowski Carl | Chief Medical Officer | Exercise or conversion | 4K | $22.86 | $94K | 217K |
| 2026-02-02 | Henderson Jane | Chief Financial Officer | Sell | 100 | $66.89 | $7K | 183K |
| 2026-02-02 | Henderson Jane | Chief Financial Officer | Sell | 1K | $66.15 | $73K | 183K |
| 2026-02-02 | Henderson Jane | Chief Financial Officer | Sell | 792 | $65.21 | $52K | 185K |
| 2026-01-22 | Harwin Peter Evan | Director | Sell | 1.8M | $76.30 | $133.5M | 299K |
| 2026-01-22 | Fairmount Funds Management LLC | Director | Sell | 1.8M | $76.30 | $133.5M | 299K |
| 2026-01-14 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 470 | $83.79 | $39K | 1.2M |
| 2026-01-14 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 5K | $83.16 | $448K | 1.2M |
| 2026-01-14 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 2K | $82.41 | $153K | 1.2M |
| 2026-01-14 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 2K | $81.00 | $192K | 1.2M |
| 2026-01-14 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 8K | $79.82 | $677K | 1.2M |
| 2026-01-14 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 1K | $78.64 | $113K | 1.2M |
| 2026-01-07 | Dambkowski Carl | Chief Medical Officer | Sell | 100 | $80.06 | $8K | 213K |
| 2026-01-07 | Dambkowski Carl | Chief Medical Officer | Sell | 826 | $79.04 | $65K | 213K |
| 2026-01-07 | Dambkowski Carl | Chief Medical Officer | Sell | 15K | $77.90 | $1.2M | 213K |
| 2026-01-07 | Dambkowski Carl | Chief Medical Officer | Sell | 3K | $77.13 | $228K | 228K |
| 2026-01-07 | Dambkowski Carl | Chief Medical Officer | Exercise or conversion | 14K | $22.86 | $321K | 231K |
| 2026-01-06 | Henderson Jane | Chief Financial Officer | Sell | 2K | $80.00 | $160K | 185K |
| 2026-01-02 | Henderson Jane | Chief Financial Officer | Sell | 4K | $75.20 | $307K | 187K |
| 2026-01-02 | Henderson Jane | Chief Financial Officer | Sell | 2K | $74.13 | $142K | 191K |
| 2025-12-19 | Henderson Jane | Chief Financial Officer | Sell | 2K | $80.00 | $120K | 193K |
| 2025-12-10 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 560 | $76.58 | $43K | 1.2M |
| 2025-12-10 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 10K | $75.79 | $758K | 1.2M |
| 2025-12-10 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 9K | $74.88 | $706K | 1.2M |
| 2025-12-04 | Dambkowski Carl | Chief Medical Officer | Sell | 11K | $75.00 | $818K | 271K |
| 2025-12-04 | Henderson Jane | Chief Financial Officer | Sell | 2K | $75.00 | $113K | 195K |
| 2025-12-04 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 40K | $75.01 | $3.0M | 1.2M |
| 2025-11-25 | Henderson Jane | Chief Financial Officer | Sell | 2K | $70.00 | $105K | 196K |
| 2025-11-14 | Henderson Jane | Chief Financial Officer | Sell | 2K | $65.00 | $130K | 198K |
| 2025-11-13 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 100 | $64.52 | $6K | 1.3M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON19 Form 144 notices on file for APGE worth $171.2M at the prices reported; 0 in the last 90 days worth $0. Latest: CARL DAMBKOWSKI filed on 2026-07-01 to sell 16,500 shares ($2.2M) from 2026-07-01.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-07-01 | CARL DAMBKOWSKIOfficer | 17K | $2.2M | 0.027% | 2026-07-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-22 | CARL DAMBKOWSKIOfficer | 15K | $1.4M | 0.025% | 2026-06-22 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-22 | HENDERSON MICHAEL THOMASOfficer, Director | 80K | $10.6M | 0.129% | 2026-06-22 | THE CHARLES SCHWAB CORPORATION |
| 2026-05-13 | HENDERSON MICHAEL THOMASOfficer, Director | 60K | $4.9M | 0.080% | 2026-05-13 | THE CHARLES SCHWAB CORPORATION |
| 2026-05-06 | CARL DAMBKOWSKIOfficer | 22K | $1.8M | 0.032% | 2026-05-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-01 | JANE HENDERSONOfficer | 2K | $166K | 0.004% | 2026-05-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-25 | JANE HENDERSONOfficer | 6K | $438K | 0.011% | 2026-03-25 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-11 | HENDERSON MICHAEL THOMASOfficer, Director | 60K | $3.8M | 0.109% | 2026-02-11 | THE CHARLES SCHWAB CORPORATION |
| 2026-01-22 | Fairmount Healthcare Fund II L.P.Director | 1.8M | $133.5M | 3.191% | 2026-01-22 | Jefferies LLC |
| 2026-01-07 | CARL DAMBKOWSKIOfficer | 35K | $2.8M | 0.052% | 2026-01-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-02 | JANE HENDERSONOfficer | 12K | $906K | 0.018% | 2026-01-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-19 | JANE HENDERSONOfficer | 2K | $116K | 0.002% | 2025-12-19 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-04 | JANE HENDERSONOfficer | 2K | $112K | 0.002% | 2025-12-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-04 | CARL DAMBKOWSKIOfficer | 11K | $813K | 0.016% | 2025-12-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-25 | JANE HENDERSONOfficer | 2K | $102K | 0.002% | 2025-11-25 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-14 | JANE HENDERSONOfficer | 2K | $126K | 0.003% | 2025-11-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-13 | HENDERSON MICHAEL THOMASOfficer, Director | 100K | $6.7M | 0.146% | 2025-11-13 | THE CHARLES SCHWAB CORPORATION |
| 2025-11-12 | JANE HENDERSONOfficer | 1K | $57K | 0.001% | 2025-11-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-05 | CARL DAMBKOWSKIOfficer | 11K | $581K | 0.018% | 2025-11-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON1 holder reports 5% or more of APGE in its latest filing, on Schedule 13G (passive). The holder is Wellington Management Company LLP at 8.3% of the class (4,746,585 shares), filed 2026-02-10 for an event on 2025-12-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-09-08 | 13D/Ano. 1 | VHCP Co-Investment Holdings III, LLCother entity | 0 | 0.0% | 2026-09-03 |
| 2026-09-08 | 13D/Ano. 1 | Venrock Healthcare Capital Partners III, L.P.partnership | 0 | 0.0% | 2026-09-03 |
| 2026-09-08 | 13D/Ano. 1 | Venrock Healthcare Capital Partners EG, L.P.partnership | 0 | 0.0% | 2026-09-03 |
| 2026-09-08 | 13D/Ano. 1 | VHCP Management III, LLCother entity | 0 | 0.0% | 2026-09-03 |
| 2026-09-08 | 13D/Ano. 1 | VHCP Management EG, LLCother entity | 0 | 0.0% | 2026-09-03 |
| 2026-09-08 | 13D/Ano. 1 | Bong Y. Kohindividual | 0 | 0.0% | 2026-09-03 |
| 2026-09-08 | 13D/Ano. 1 | Nimish Shahindividual | 0 | 0.0% | 2026-09-03 |
| 2026-09-03 | 13D/Ano. 7 | Fairmount Healthcare Fund II L.P.partnership | 0 | 0.0% | 2026-09-03 |
| 2026-09-03 | 13D/Ano. 7 | Fairmount Funds Management LLCinvestment adviser | 0 | 0.0% | 2026-09-03 |
| 2026-09-03 | 13D/Ano. 7 | Peter Evan Harwinindividual, parent holding company | 0 | 0.0% | 2026-09-03 |
| 2026-09-03 | 13D/Ano. 7 | Tomas Kiselakindividual, parent holding company | 0 | 0.0% | 2026-09-03 |
| 2026-07-08 | 13G/Ano. 2 | T. Rowe Price Investment Management, Inc.investment adviser | 773K | 1.3% | 2026-06-30 |
| 2026-07-08 | 13G/Ano. 5 | Wellington Investment Advisors Holdings LLPparent holding company | 564K | 0.9% | 2026-06-30 |
| 2026-07-08 | 13G/Ano. 5 | Wellington Group Holdings LLPparent holding company | 564K | 0.9% | 2026-06-30 |
| 2026-07-08 | 13G/Ano. 5 | Wellington Management Group LLPparent holding company | 564K | 0.9% | 2026-06-30 |
| 2026-07-08 | 13G/Ano. 4 | Abigail P. Johnsonindividual | 2.5M | 4.0% | 2026-06-30 |
| 2026-07-08 | 13G/Ano. 4 | FMR LLCparent holding company | 2.5M | 4.0% | 2026-06-30 |
| 2026-03-26 | 13G/Ano. 1 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-17 | 13G/Ano. 1 | RTW Investments, LPinvestment adviser, partnership | 2.7M | 4.9% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Roderick Wongparent holding company, individual | 2.7M | 4.9% | 2025-12-31 |
| 2026-02-10 | 13G/Ano. 4 | Wellington Management Company LLPinvestment adviser | 4.7M | 8.3% | 2025-12-31 |
| 2025-11-14 | 13G/Ano. 1 | DRIEHAUS CAPITAL MANAGEMENT LLCinvestment adviser | 2.2M | 4.7% | 2025-09-30 |
13F holders
Tracked managers holding APGE at their latest 13F. JSON8 of the 30 tracked managers held APGE at their latest 13F, $351.7M in total at quarter-end prices. Millennium Management is the largest at $198.0M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Millennium Management | 2026-06-30 | 1.5M | $198.0M | 0.07% | +1.4M |
| Soros Fund Management | 2026-06-30 | 565K | $74.9M | 0.92% | new |
| D. E. Shaw & Co. | 2026-06-30 | 246K | $32.7M | 0.02% | +187K |
| Renaissance Technologies | 2026-06-30 | 147K | $19.5M | 0.03% | new |
| Two Sigma Investments | 2026-06-30 | 95K | $12.6M | 0.01% | -187K |
| Point72 Asset Management | 2026-06-30 | 55K | $7.2M | 0.01% | new |
| Citadel Advisors | 2026-06-30 | 44K | $5.8M | 0.00% | -555K |
| AQR Capital Management | 2026-06-30 | 8K | $1.1M | 0.00% | -69 |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Apogee Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Apogee Therapeutics (APGE), SEC CIK 1974640, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-08-31.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-09-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-03.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-07-01.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-09-08.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-10.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-03.JSON and CSV
- Company record
- EDGAR filing index for CIK 1974640Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
Other company pages
Datasets
Frequently Asked Questions
How much of APGE is sold short?
4,203,052 shares were held short at the 2026-08-31 settlement, 3.5 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is APGE's daily short volume?
On 2026-09-02, 142,078 of the 340,503 APGE shares reported to FINRA were sold short, 41.7% of the day's reported volume. Short volume is a flow for one day, not a position.
Does APGE have fails to deliver?
The SEC's latest file shows 1 APGE shares failed to deliver at settlement 2026-09-03. Fails are reported per settlement date and published twice a month with a lag.
Are APGE insiders buying or selling?
Insiders at APGE reported 1 open-market sell worth $738K in the last 90 days and no open-market buys. Latest filing: Fairmount Funds Management LLC (Director) on 2026-09-03.
Have APGE insiders filed to sell?
19 Form 144 notices on file for APGE worth $171.2M at the prices reported; 0 in the last 90 days worth $0. Latest: CARL DAMBKOWSKI filed on 2026-07-01 to sell 16,500 shares ($2.2M) from 2026-07-01.
Who owns 5% or more of APGE?
1 holder reports 5% or more of APGE in its latest filing, on Schedule 13G (passive). The holder is Wellington Management Company LLP at 8.3% of the class (4,746,585 shares), filed 2026-02-10 for an event on 2025-12-31.
Which tracked 13F managers own APGE?
8 of the 30 tracked 13F managers held APGE shares at their latest filing, $351.7M in all. The largest: Izzy Englander's Millennium Management (1.5M shares, $198.0M), George Soros's Soros Fund Management (565K shares, $74.9M), D. E. Shaw & Co. (246K shares, $32.7M), Renaissance Technologies (147K shares, $19.5M), Two Sigma Investments (95K shares, $12.6M), Steve Cohen's Point72 Asset Management (55K shares, $7.2M). The table above lists all 8.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.